Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Novartis
Hutchmed
Servier
Ikena Oncology
National Cancer Institute (NCI)
Deciphera Pharmaceuticals, LLC
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Polaris Group
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Emory University
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
Envita Medical Center, Inc.
TransMolecular
Thallion Pharmaceuticals